icon-folder.gif   Conference Reports for NATAP  
 
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
 
 
 
Outcome of Treatment with Peginterferon alfa-2a (40KD) in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B (CHB) in the Real-World: Interim Analysis of Data from the Large European S-Collate Cohort
 
 
  Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
 
P. Marcellin,1 M.G. Curescu,2 A. Piekarska,3 W.W. Mazur,4 C. Hezode,5 D. Guyader,6 C. Jochum,7 G.R. Foster,8 D. Ouzan,9 M. Cornberg,10 M. Bogdan,11 D. Messinger,12 V. Cartier,13 J. Petersen;14 on behalf of the S-Collate study group 1Service d'Hepatologie and INSERM CRB3/U773, Universite Paris-Diderot, Clichy, France; 2Department of Infectious Diseases, University of Medicine and Pharmacy, Timisoara, Romania; 3Department of Infectious Diseases and Hepatology, Medical University of Lodz, Lodz, Poland; 4Infectious Disease Department, Medical University of Silesia, Katowice, Poland; 5Department of Hepatology and Gastroenterology, H˘pital Henri Mondor, Universite Paris-Est, Creteil, France; 6Clinique des Maladies du Foie and INSERM U 49, CHRU Pontchaillou, Rennes, France; 7Department of Gastroenterology and Hepatology, University Duisberg-Essen, Essen, Germany; 8The Liver Unit, Queen Mary, University of London, London, United Kingdom; 9Institut Arnault Tzanck, Saint-Laurent-du-Var, France; 10Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany; 11Roche Pharma AG, Grenzach, Germany; 12IST GmbH, Mannheim, Germany; 13Roche S.A.S., Boulogne-Billancourt, France; 14Liver Unit IFI Institute, Asklepios Klinik St. Georg, Hamburg, Germany

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

References
 
1. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
 
2. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61.
 
3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
 
4. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
 
5. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
 
6. Liaw YF, Jia JD, Chan HLY, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011; 54: 1591-9.
 
7. Marcellin P, Bonino F, Yurdaydin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 2013; 7: 88-97.
 
8. Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 1084-92.
 
9. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-10.